# Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer

> **NCT04984733** · PHASE2 · COMPLETED · sponsor: **University of Southampton** · enrollment: 13 (actual)

## Conditions studied

- Adenocarcinoma - GEJ
- Cancer of Esophagus

## Interventions

- **DRUG:** Temozolomide
- **DRUG:** Temozolomide 50mg/m2/day
- **DRUG:** Temozolomide 3 month
- **DRUG:** Temozolomide 24month

## Key facts

- **NCT ID:** NCT04984733
- **Lead sponsor:** University of Southampton
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-09-28
- **Primary completion:** 2024-10-23
- **Final completion:** 2024-10-23
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04984733

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04984733, "Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04984733. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*